Correlation Between Arcus Biosciences and Atara Biotherapeutics

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Arcus Biosciences and Atara Biotherapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Arcus Biosciences and Atara Biotherapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Arcus Biosciences and Atara Biotherapeutics, you can compare the effects of market volatilities on Arcus Biosciences and Atara Biotherapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Arcus Biosciences with a short position of Atara Biotherapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Arcus Biosciences and Atara Biotherapeutics.

Diversification Opportunities for Arcus Biosciences and Atara Biotherapeutics

0.72
  Correlation Coefficient

Poor diversification

The 3 months correlation between Arcus and Atara is 0.72. Overlapping area represents the amount of risk that can be diversified away by holding Arcus Biosciences and Atara Biotherapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Atara Biotherapeutics and Arcus Biosciences is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Arcus Biosciences are associated (or correlated) with Atara Biotherapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Atara Biotherapeutics has no effect on the direction of Arcus Biosciences i.e., Arcus Biosciences and Atara Biotherapeutics go up and down completely randomly.

Pair Corralation between Arcus Biosciences and Atara Biotherapeutics

Given the investment horizon of 90 days Arcus Biosciences is expected to under-perform the Atara Biotherapeutics. But the stock apears to be less risky and, when comparing its historical volatility, Arcus Biosciences is 2.39 times less risky than Atara Biotherapeutics. The stock trades about -0.23 of its potential returns per unit of risk. The Atara Biotherapeutics is currently generating about -0.05 of returns per unit of risk over similar time horizon. If you would invest  1,215  in Atara Biotherapeutics on December 27, 2024 and sell it today you would lose (527.00) from holding Atara Biotherapeutics or give up 43.37% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthSignificant
Accuracy100.0%
ValuesDaily Returns

Arcus Biosciences  vs.  Atara Biotherapeutics

 Performance 
       Timeline  
Arcus Biosciences 

Risk-Adjusted Performance

Very Weak

 
Weak
 
Strong
Over the last 90 days Arcus Biosciences has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in April 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.
Atara Biotherapeutics 

Risk-Adjusted Performance

Very Weak

 
Weak
 
Strong
Over the last 90 days Atara Biotherapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite unsteady performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in April 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

Arcus Biosciences and Atara Biotherapeutics Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Arcus Biosciences and Atara Biotherapeutics

The main advantage of trading using opposite Arcus Biosciences and Atara Biotherapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Arcus Biosciences position performs unexpectedly, Atara Biotherapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Atara Biotherapeutics will offset losses from the drop in Atara Biotherapeutics' long position.
The idea behind Arcus Biosciences and Atara Biotherapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.

Other Complementary Tools

AI Portfolio Architect
Use AI to generate optimal portfolios and find profitable investment opportunities
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance